Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)
This study assessed the effects of gonadotropin-releasing hormone agonists (GnRHa) on the prevention of chemotherapy-induced ovarian insufficiency among young patients with malignant ovarian germ cell tumour (MOGCT) receiving chemotherapy. This multicentre, retrospective study was conducted at 15 si...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2020-07, Vol.133, p.56-65 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 65 |
|---|---|
| container_issue | |
| container_start_page | 56 |
| container_title | European journal of cancer (1990) |
| container_volume | 133 |
| creator | Choi, Min C. Chung, Young S. Lee, Jeong-Won Kwon, Byung S. Park, Byung K. Kim, Se I. Shim, Seung-Hyuk Lee, Kwang-Beom Seong, Seok J. Lee, Sung J. Lee, San H. Yoo, Heon-Jong Song, Taejong Kim, Min K. Baek, Min-Hyun Kang, Sokbom Kim, Yong-Man |
| description | This study assessed the effects of gonadotropin-releasing hormone agonists (GnRHa) on the prevention of chemotherapy-induced ovarian insufficiency among young patients with malignant ovarian germ cell tumour (MOGCT) receiving chemotherapy.
This multicentre, retrospective study was conducted at 15 sites affiliated with the Korean Gynecologic Oncology Group and enrolled 354 patients between January 1995 and September 2018. Among them, 227 patients were included in this study and divided into two groups according to the use of GnRHa during chemotherapy (GnRHa versus no GnRHa groups). The primary objective was to compare the rates of menstrual resumption between the two groups. We also assessed the clinical determinants affecting menstrual resumption among the study groups.
There were no significant differences between the GnRHa (n = 63) and no GnRHa (n = 164) groups regarding age at diagnosis, parity, ethnicity, age at menarche, body mass index, International Federation of Gynecology and Obstetrics stage, mode of surgery and surgery type. The rate of menstrual resumption after chemotherapy was 100% (63 of 63) in the GnRHa group and 90.9% (149 of 164) in the no GnRHa group (p = 0.013). The mean periods from last chemotherapy to menstrual resumption were 7.4 and 7.3 months in the GnRHa and no GnRHa groups, respectively. GnRHa co-administration during chemotherapy reduced the likelihood of amenorrhoea after chemotherapy, although statistical significance was not confirmed in the univariate analysis (odds ratio: 0.276; 95% confidence interval, 0.004–1.317; p = 0.077).
Temporary ovarian suppression with GnRHa during chemotherapy does not significantly increase the chances of menstrual resumption in young patients with MOGCT.
•GnRH analogues appear to increase non-significantly the chances of menstrual recovery.•The average time to menstrual recovery is unaffected by GnRH analogues. |
| doi_str_mv | 10.1016/j.ejca.2020.03.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_pubmed_primary_32442924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804920302094</els_id><sourcerecordid>2442964392</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-8701e19e8385577e2833ac2434298c0b994c52169af2777e8bd836b03a5fdf2c3</originalsourceid><addsrcrecordid>eNp9UdGK1DAULaK44-oP-CABX9aHjrdJ2qbgiyzuKC4siD6HNL2dSWmTmqQj84N-l-nOug8-CBcS7j3n3Ms5Wfa6gG0BRfV-2OKg1ZYChS2wVPAk2xSibnIQJX2abaApm1wAby6yFyEMAFALDs-zC0Y5pw3lm-z3DapgWjOaeCLKdgT73milT8T1ZO-s6lz0bjY29ziuULsnB-cnZ5GoNDchBtI7T-IByezxiDYaZ1e2PuDkUtur-ZQb2y0aO-KOyhtlibFhWTcZtGmXsWRWMf2T2C8TD2RSo9lbZeMjYY9-IhrHkcRlcosP5Orr7m5HGHDx7d3L7FmvxoCvHt7L7MfNp-_Xn_Pbu92X64-3uWaCx1zUUGDRoGCiLOsaqWBMacpZckNoaJuG65IWVaN6Wqe5aDvBqhaYKvuup5pdZldn3dm7nwuGKCcT1quURbcESTlUDFhNaYK-_Qc6pLNtuk7eu19x1qwoekZp70Lw2MvZm0n5kyxArinLQa4pyzVlCSwVJNKbB-mlnbB7pPyNNQE-nAGYvDga9DLcO42d8aij7Jz5n_4fOza7XQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442964392</pqid></control><display><type>article</type><title>Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Choi, Min C. ; Chung, Young S. ; Lee, Jeong-Won ; Kwon, Byung S. ; Park, Byung K. ; Kim, Se I. ; Shim, Seung-Hyuk ; Lee, Kwang-Beom ; Seong, Seok J. ; Lee, Sung J. ; Lee, San H. ; Yoo, Heon-Jong ; Song, Taejong ; Kim, Min K. ; Baek, Min-Hyun ; Kang, Sokbom ; Kim, Yong-Man</creator><creatorcontrib>Choi, Min C. ; Chung, Young S. ; Lee, Jeong-Won ; Kwon, Byung S. ; Park, Byung K. ; Kim, Se I. ; Shim, Seung-Hyuk ; Lee, Kwang-Beom ; Seong, Seok J. ; Lee, Sung J. ; Lee, San H. ; Yoo, Heon-Jong ; Song, Taejong ; Kim, Min K. ; Baek, Min-Hyun ; Kang, Sokbom ; Kim, Yong-Man</creatorcontrib><description>This study assessed the effects of gonadotropin-releasing hormone agonists (GnRHa) on the prevention of chemotherapy-induced ovarian insufficiency among young patients with malignant ovarian germ cell tumour (MOGCT) receiving chemotherapy.
This multicentre, retrospective study was conducted at 15 sites affiliated with the Korean Gynecologic Oncology Group and enrolled 354 patients between January 1995 and September 2018. Among them, 227 patients were included in this study and divided into two groups according to the use of GnRHa during chemotherapy (GnRHa versus no GnRHa groups). The primary objective was to compare the rates of menstrual resumption between the two groups. We also assessed the clinical determinants affecting menstrual resumption among the study groups.
There were no significant differences between the GnRHa (n = 63) and no GnRHa (n = 164) groups regarding age at diagnosis, parity, ethnicity, age at menarche, body mass index, International Federation of Gynecology and Obstetrics stage, mode of surgery and surgery type. The rate of menstrual resumption after chemotherapy was 100% (63 of 63) in the GnRHa group and 90.9% (149 of 164) in the no GnRHa group (p = 0.013). The mean periods from last chemotherapy to menstrual resumption were 7.4 and 7.3 months in the GnRHa and no GnRHa groups, respectively. GnRHa co-administration during chemotherapy reduced the likelihood of amenorrhoea after chemotherapy, although statistical significance was not confirmed in the univariate analysis (odds ratio: 0.276; 95% confidence interval, 0.004–1.317; p = 0.077).
Temporary ovarian suppression with GnRHa during chemotherapy does not significantly increase the chances of menstrual resumption in young patients with MOGCT.
•GnRH analogues appear to increase non-significantly the chances of menstrual recovery.•The average time to menstrual recovery is unaffected by GnRH analogues.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2020.03.030</identifier><identifier>PMID: 32442924</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Agonists ; Body mass ; Body mass index ; Body size ; Chemotherapy ; Confidence intervals ; Gonadotropin releasing hormone agonist ; Gonadotropin-releasing hormone ; Gonadotropins ; Gynecology ; Menarche ; Menstruation ; Minority & ethnic groups ; Obstetrics ; Oncology ; Ovarian germ cell cancer ; Ovarian insufficiency ; Ovaries ; Patients ; Pituitary (anterior) ; Prevention ; Statistical analysis ; Surgery ; Tumors</subject><ispartof>European journal of cancer (1990), 2020-07, Vol.133, p.56-65</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jul 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-8701e19e8385577e2833ac2434298c0b994c52169af2777e8bd836b03a5fdf2c3</citedby><cites>FETCH-LOGICAL-c384t-8701e19e8385577e2833ac2434298c0b994c52169af2777e8bd836b03a5fdf2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2020.03.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32442924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Min C.</creatorcontrib><creatorcontrib>Chung, Young S.</creatorcontrib><creatorcontrib>Lee, Jeong-Won</creatorcontrib><creatorcontrib>Kwon, Byung S.</creatorcontrib><creatorcontrib>Park, Byung K.</creatorcontrib><creatorcontrib>Kim, Se I.</creatorcontrib><creatorcontrib>Shim, Seung-Hyuk</creatorcontrib><creatorcontrib>Lee, Kwang-Beom</creatorcontrib><creatorcontrib>Seong, Seok J.</creatorcontrib><creatorcontrib>Lee, Sung J.</creatorcontrib><creatorcontrib>Lee, San H.</creatorcontrib><creatorcontrib>Yoo, Heon-Jong</creatorcontrib><creatorcontrib>Song, Taejong</creatorcontrib><creatorcontrib>Kim, Min K.</creatorcontrib><creatorcontrib>Baek, Min-Hyun</creatorcontrib><creatorcontrib>Kang, Sokbom</creatorcontrib><creatorcontrib>Kim, Yong-Man</creatorcontrib><title>Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>This study assessed the effects of gonadotropin-releasing hormone agonists (GnRHa) on the prevention of chemotherapy-induced ovarian insufficiency among young patients with malignant ovarian germ cell tumour (MOGCT) receiving chemotherapy.
This multicentre, retrospective study was conducted at 15 sites affiliated with the Korean Gynecologic Oncology Group and enrolled 354 patients between January 1995 and September 2018. Among them, 227 patients were included in this study and divided into two groups according to the use of GnRHa during chemotherapy (GnRHa versus no GnRHa groups). The primary objective was to compare the rates of menstrual resumption between the two groups. We also assessed the clinical determinants affecting menstrual resumption among the study groups.
There were no significant differences between the GnRHa (n = 63) and no GnRHa (n = 164) groups regarding age at diagnosis, parity, ethnicity, age at menarche, body mass index, International Federation of Gynecology and Obstetrics stage, mode of surgery and surgery type. The rate of menstrual resumption after chemotherapy was 100% (63 of 63) in the GnRHa group and 90.9% (149 of 164) in the no GnRHa group (p = 0.013). The mean periods from last chemotherapy to menstrual resumption were 7.4 and 7.3 months in the GnRHa and no GnRHa groups, respectively. GnRHa co-administration during chemotherapy reduced the likelihood of amenorrhoea after chemotherapy, although statistical significance was not confirmed in the univariate analysis (odds ratio: 0.276; 95% confidence interval, 0.004–1.317; p = 0.077).
Temporary ovarian suppression with GnRHa during chemotherapy does not significantly increase the chances of menstrual resumption in young patients with MOGCT.
•GnRH analogues appear to increase non-significantly the chances of menstrual recovery.•The average time to menstrual recovery is unaffected by GnRH analogues.</description><subject>Agonists</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Gonadotropin releasing hormone agonist</subject><subject>Gonadotropin-releasing hormone</subject><subject>Gonadotropins</subject><subject>Gynecology</subject><subject>Menarche</subject><subject>Menstruation</subject><subject>Minority & ethnic groups</subject><subject>Obstetrics</subject><subject>Oncology</subject><subject>Ovarian germ cell cancer</subject><subject>Ovarian insufficiency</subject><subject>Ovaries</subject><subject>Patients</subject><subject>Pituitary (anterior)</subject><subject>Prevention</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9UdGK1DAULaK44-oP-CABX9aHjrdJ2qbgiyzuKC4siD6HNL2dSWmTmqQj84N-l-nOug8-CBcS7j3n3Ms5Wfa6gG0BRfV-2OKg1ZYChS2wVPAk2xSibnIQJX2abaApm1wAby6yFyEMAFALDs-zC0Y5pw3lm-z3DapgWjOaeCLKdgT73milT8T1ZO-s6lz0bjY29ziuULsnB-cnZ5GoNDchBtI7T-IByezxiDYaZ1e2PuDkUtur-ZQb2y0aO-KOyhtlibFhWTcZtGmXsWRWMf2T2C8TD2RSo9lbZeMjYY9-IhrHkcRlcosP5Orr7m5HGHDx7d3L7FmvxoCvHt7L7MfNp-_Xn_Pbu92X64-3uWaCx1zUUGDRoGCiLOsaqWBMacpZckNoaJuG65IWVaN6Wqe5aDvBqhaYKvuup5pdZldn3dm7nwuGKCcT1quURbcESTlUDFhNaYK-_Qc6pLNtuk7eu19x1qwoekZp70Lw2MvZm0n5kyxArinLQa4pyzVlCSwVJNKbB-mlnbB7pPyNNQE-nAGYvDga9DLcO42d8aij7Jz5n_4fOza7XQ</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Choi, Min C.</creator><creator>Chung, Young S.</creator><creator>Lee, Jeong-Won</creator><creator>Kwon, Byung S.</creator><creator>Park, Byung K.</creator><creator>Kim, Se I.</creator><creator>Shim, Seung-Hyuk</creator><creator>Lee, Kwang-Beom</creator><creator>Seong, Seok J.</creator><creator>Lee, Sung J.</creator><creator>Lee, San H.</creator><creator>Yoo, Heon-Jong</creator><creator>Song, Taejong</creator><creator>Kim, Min K.</creator><creator>Baek, Min-Hyun</creator><creator>Kang, Sokbom</creator><creator>Kim, Yong-Man</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20200701</creationdate><title>Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)</title><author>Choi, Min C. ; Chung, Young S. ; Lee, Jeong-Won ; Kwon, Byung S. ; Park, Byung K. ; Kim, Se I. ; Shim, Seung-Hyuk ; Lee, Kwang-Beom ; Seong, Seok J. ; Lee, Sung J. ; Lee, San H. ; Yoo, Heon-Jong ; Song, Taejong ; Kim, Min K. ; Baek, Min-Hyun ; Kang, Sokbom ; Kim, Yong-Man</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-8701e19e8385577e2833ac2434298c0b994c52169af2777e8bd836b03a5fdf2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Agonists</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Gonadotropin releasing hormone agonist</topic><topic>Gonadotropin-releasing hormone</topic><topic>Gonadotropins</topic><topic>Gynecology</topic><topic>Menarche</topic><topic>Menstruation</topic><topic>Minority & ethnic groups</topic><topic>Obstetrics</topic><topic>Oncology</topic><topic>Ovarian germ cell cancer</topic><topic>Ovarian insufficiency</topic><topic>Ovaries</topic><topic>Patients</topic><topic>Pituitary (anterior)</topic><topic>Prevention</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Min C.</creatorcontrib><creatorcontrib>Chung, Young S.</creatorcontrib><creatorcontrib>Lee, Jeong-Won</creatorcontrib><creatorcontrib>Kwon, Byung S.</creatorcontrib><creatorcontrib>Park, Byung K.</creatorcontrib><creatorcontrib>Kim, Se I.</creatorcontrib><creatorcontrib>Shim, Seung-Hyuk</creatorcontrib><creatorcontrib>Lee, Kwang-Beom</creatorcontrib><creatorcontrib>Seong, Seok J.</creatorcontrib><creatorcontrib>Lee, Sung J.</creatorcontrib><creatorcontrib>Lee, San H.</creatorcontrib><creatorcontrib>Yoo, Heon-Jong</creatorcontrib><creatorcontrib>Song, Taejong</creatorcontrib><creatorcontrib>Kim, Min K.</creatorcontrib><creatorcontrib>Baek, Min-Hyun</creatorcontrib><creatorcontrib>Kang, Sokbom</creatorcontrib><creatorcontrib>Kim, Yong-Man</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Min C.</au><au>Chung, Young S.</au><au>Lee, Jeong-Won</au><au>Kwon, Byung S.</au><au>Park, Byung K.</au><au>Kim, Se I.</au><au>Shim, Seung-Hyuk</au><au>Lee, Kwang-Beom</au><au>Seong, Seok J.</au><au>Lee, Sung J.</au><au>Lee, San H.</au><au>Yoo, Heon-Jong</au><au>Song, Taejong</au><au>Kim, Min K.</au><au>Baek, Min-Hyun</au><au>Kang, Sokbom</au><au>Kim, Yong-Man</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>133</volume><spage>56</spage><epage>65</epage><pages>56-65</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>This study assessed the effects of gonadotropin-releasing hormone agonists (GnRHa) on the prevention of chemotherapy-induced ovarian insufficiency among young patients with malignant ovarian germ cell tumour (MOGCT) receiving chemotherapy.
This multicentre, retrospective study was conducted at 15 sites affiliated with the Korean Gynecologic Oncology Group and enrolled 354 patients between January 1995 and September 2018. Among them, 227 patients were included in this study and divided into two groups according to the use of GnRHa during chemotherapy (GnRHa versus no GnRHa groups). The primary objective was to compare the rates of menstrual resumption between the two groups. We also assessed the clinical determinants affecting menstrual resumption among the study groups.
There were no significant differences between the GnRHa (n = 63) and no GnRHa (n = 164) groups regarding age at diagnosis, parity, ethnicity, age at menarche, body mass index, International Federation of Gynecology and Obstetrics stage, mode of surgery and surgery type. The rate of menstrual resumption after chemotherapy was 100% (63 of 63) in the GnRHa group and 90.9% (149 of 164) in the no GnRHa group (p = 0.013). The mean periods from last chemotherapy to menstrual resumption were 7.4 and 7.3 months in the GnRHa and no GnRHa groups, respectively. GnRHa co-administration during chemotherapy reduced the likelihood of amenorrhoea after chemotherapy, although statistical significance was not confirmed in the univariate analysis (odds ratio: 0.276; 95% confidence interval, 0.004–1.317; p = 0.077).
Temporary ovarian suppression with GnRHa during chemotherapy does not significantly increase the chances of menstrual resumption in young patients with MOGCT.
•GnRH analogues appear to increase non-significantly the chances of menstrual recovery.•The average time to menstrual recovery is unaffected by GnRH analogues.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32442924</pmid><doi>10.1016/j.ejca.2020.03.030</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2020-07, Vol.133, p.56-65 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_pubmed_primary_32442924 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Agonists Body mass Body mass index Body size Chemotherapy Confidence intervals Gonadotropin releasing hormone agonist Gonadotropin-releasing hormone Gonadotropins Gynecology Menarche Menstruation Minority & ethnic groups Obstetrics Oncology Ovarian germ cell cancer Ovarian insufficiency Ovaries Patients Pituitary (anterior) Prevention Statistical analysis Surgery Tumors |
| title | Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A50%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20and%20efficacy%20of%20gonadotropin-releasing%20hormone%20agonists%20for%20the%20prevention%20of%20chemotherapy-induced%20ovarian%20insufficiency%20in%20patients%20with%20malignant%20ovarian%20germ%20cell%20tumours%20(KGOG%203048R)&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Choi,%20Min%20C.&rft.date=2020-07-01&rft.volume=133&rft.spage=56&rft.epage=65&rft.pages=56-65&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2020.03.030&rft_dat=%3Cproquest_cross%3E2442964392%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442964392&rft_id=info:pmid/32442924&rft_els_id=S0959804920302094&rfr_iscdi=true |